GSK1324726A-SDS-MedChemExpress
进口药品注册标准目录2
甘氨酸 固体脂肪36型 固体脂肪38型 共聚维酮 H 黄凡士林 滑石粉
糊精
药品生产企业使用药用辅料调查情况汇总表
镇江市环宇药用辅料厂 海盐六和淀粉化工有限公司 嘉兴市白浪淀粉制品有限公司 华北制药康欣有限公司 安徽山河药用辅料有限公司 河南精忠威尔药业有限公司 J 甲基丙烯酸-丙烯酸乙酯 Rohm GmbH & Co.KG (德国进口) 共聚物水分散体 甲基丙烯酸共聚物A型 Rohm GmbH & Co.KG (德国进口) 聚维酮K30 湖州展望药业有限公司 BASF Corporation (美国进口) 安徽山河药用辅料有限公司 博爱新开源制药有限公司 海南南杭药业有限公司 聚山梨酯80(吐温80) 南京威尔化工有限公司 上海申宇医药化工有限公司 龙游聚兴粮油医药化工有限公司 北京市海淀会友精细化工厂 南京威尔化工有限公司 辽阳奥克纳米材料有限公司 北京海淀会友精细化工厂 上海浦东高南化工厂 南京威尔化工有限公司 International Specialty Products Inc. ( 美 国进口) 连云港华瑞化工有限责任公司 INTERNATIONAL SPECIALTY PRODUCTS INC.(美国进口) 苏卫药准字(94)第3022-2号 浙卫药准字(1998)第220902号 浙卫药准字(1996)第220901号 冀卫药准字(1995)第000057号 皖药准字(2002)第F0001号 豫药准字F20040002号 进口药品注册证号:H20060013 进口药品注册证号:H20060593 浙药准字F20060062号 进口药品注册证号:H20040430 皖药准字F20060001 (95)卫药准字F-01号 琼药准字F20040001 苏卫药准字(2001)第423201号 沪卫药准字(1995)第186001号 浙卫药准字(1996)第184101号 京卫药准字(95)第023号 苏卫药准字(2001)第423301号 辽药准字F(2004)第900033号 京卫药准字(95)第008号 沪卫药准字(1995)第105004号 苏卫药准字(2001)第423601号 进口药品注册证号:H20030492 苏卫药准字(1983)第308001号 进口药品注册证号:H20030278 第 3 页 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 进口药用辅料注册标准 JX20020020 进口药品注册标准 JX20020322 《中国药典》2005年版二部 进口药品注册标准 JX20030277 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 进口药品注册标准 JX20020325 《中国药典》2005年版二部 进口药品注册标准 JX19990242
Gap-26-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Mar.-13-2019Print Date:Mar.-13-20191. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Gap 26Catalog No. :HY-P1082CAS No. :197250-15-01.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:C70H106N19O19SMolecular Weight:1550.78CAS No. :197250-15-04. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Protect from lightPowder-80°C 2 years-20°C 1 yearIn solvent-80°C 6 months-20°C 1 month7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2019 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
蛋白质胶条质谱鉴定
百泰派克生物科技
蛋白质胶条质谱鉴定
蛋白质胶条鉴定
蛋白质胶条是蛋白样品经十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)后所得到的相互分离的蛋白条带。
在电场作用下,蛋白质在聚丙烯凝胶中按照分子量大小进行迁移,形成不同的蛋白条带,每一条蛋白条带中的蛋白质可能是相同的也可能是分子量相同或相似的不同蛋白质,可能是已知的也可能是未知的,这些蛋白胶条可以切割下来,对所含的蛋白质做进一步的鉴定,即蛋白质胶条鉴定。
蛋白质胶条质谱鉴定
蛋白质胶条质谱鉴定是利用质谱手段对蛋白胶条进行鉴定,常用的质谱手段包括基质辅助激光解析电离飞行时间质谱(MALDI-TOF/TOF)和高效液相串联质谱(LC-MS/MS)。
在进行质谱分析之前,需要将包埋在凝胶中的蛋白质回收提取出来,并酶解消化成肽段。
MALDI-TOF/TOF将样品均匀包埋在固体基质晶体中,基质能吸收激光的能量并将一部分能量传递给样品分子使其离子化,在电场作用下,离子加速飞过飞行管道,离子的飞行时间与质荷比(M/Z)成正比,通过检测不同离子的飞行时间可以计算其质荷比,进行多肽和蛋白鉴定。
LC-MS/MS将肽段通过高效液相色谱(HPLC)进行分离,分离后的肽段直接进入质谱仪进行分析,根据一级质谱获得的质荷比可以计算各肽段的分子质量;为了鉴定肽段的确切序列,进而拼接出各蛋白的完整序列,得到的肽段进行二级质谱分析,二级质谱数据结合相应数据库和检索软件可以推演多肽甚至蛋白的完整序列。
百泰派克生物科技采用Thermo Fisher的Orbitrap Fusion Lumos质谱平台结合nanoLC-MS/MS纳升色谱提供,能够对SDS-PAGE蛋白条带、2D蛋白胶点等样品中的蛋白质进行高效精准鉴定,欢迎免费咨询152-****7680。
双波长薄层扫描法测定大山楂咀嚼片中熊果酸的含量
双波长薄层扫描法测定大山楂咀嚼片中熊果酸的含量
熊慧敏
【期刊名称】《海峡预防医学杂志》
【年(卷),期】2003(9)3
【摘要】[目的 ]探讨测定大山楂咀嚼片中熊果酸含量的方法。
[方法 ]采用双波长薄层扫描法。
[结果 ]该法回收率10 0 86% ,RSD =1 90 %。
[结论 ]本方法操作简单方便 ,结果可靠。
【总页数】2页(P46-47)
【关键词】薄层扫描法;大山楂咀嚼片;熊果酸
【作者】熊慧敏
【作者单位】贵州省疾病预防控制中心
【正文语种】中文
【中图分类】Q658.1;R15
【相关文献】
1.薄层扫描法测定小儿山楂咀嚼片中熊果酸的含量 [J], 万义;宋晓宁
2.双波长薄层扫描法测定夏枯草中熊果酸的含量 [J], 白洁;陈翔飞;孙海峰
3.双波长薄层扫描法测定降脂胶囊中熊果酸含量 [J], 许韵梅
4.双波长薄层扫描法测定明目地黄丸中熊果酸的含量 [J], 孙晓菊;胡军林
因版权原因,仅展示原文概要,查看原文内容请购买。
核酸提取裂解液的成分 -回复
核酸提取裂解液的成分-回复核酸提取裂解液是一种常用于生物学实验中的溶液,用于裂解细胞并释放出细胞内的核酸。
它的成分通常由不同的试剂组成,每种试剂都有其特定的作用和功能。
在核酸提取裂解液中,最常见的成分是细胞裂解剂。
这些裂解剂有助于破坏细胞膜和核膜,使细胞内的核酸暴露在溶液中。
常见的细胞裂解剂包括胰酶、蛋白酶K和SDS(十二烷基硫酸钠)。
胰酶和蛋白酶K可以降解蛋白质,从而破坏细胞膜和核膜。
SDS可以破坏细胞膜,并使细胞内的蛋白质变为可溶性。
另一个常见的成分是蛋白酶抑制剂。
蛋白酶是一种能够降解蛋白质的酶类,而核酸提取实验中需要保护细胞内的蛋白质,避免其被蛋白酶降解。
因此,蛋白酶抑制剂可以抑制蛋白酶的活性,保护细胞内的蛋白质。
常见的蛋白酶抑制剂包括苯甲烷磺酰氟化合物(PMSF)、乙锡硫酰胺(DTT)和EDTA (乙二胺四乙酸)。
PMSF可以抑制广谱的蛋白酶,DTT可以还原氧化的蛋白质,而EDTA则可以结合金属离子,抑制某些金属离子依赖的蛋白酶。
此外,核酸提取裂解液中还常常添加缓冲液。
缓冲液可以调整溶液的酸碱度,使其维持在适宜的范围内。
常见的缓冲液有Tris-HCl缓冲液、PBS(磷酸盐缓冲液)和TE缓冲液(Tris-EDTA缓冲液)。
这些缓冲液可以维持细胞裂解液的pH值稳定,确保核酸提取的成功。
另外,核酸提取裂解液中还可以添加辅助剂,以增加核酸的提取效率。
辅助剂可以包括盐、酒精和有机溶剂等。
盐可以调节离子强度,有助于核酸的溶解和沉淀。
酒精和有机溶剂可以用于沉淀核酸,使其从溶液中析出。
最后,核酸提取裂解液中可能还会添加其他的试剂,例如胆固醇、RNA酶抑制剂和DNA稳定剂等。
这些试剂可以根据实验需要进行调整,以增加裂解效果或保护核酸的稳定性。
总之,核酸提取裂解液的成分多种多样,不同的试剂组合可以根据实验的需要进行调整。
这些试剂共同作用,能够有效地裂解细胞并释放出细胞内的核酸,为后续的核酸提取和分析提供可靠的基础。
Gelucire-14-44-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Nov.-23-2018Print Date:Nov.-23-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Gelucire 14/44Catalog No. :HY-Y1892CAS No. :121548-04-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:N/AMolecular Weight:N/ACAS No. :121548-04-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Pure form-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Oil)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
一种盐酸溴己新片溶出度的检测方法
一种盐酸溴己新片溶出度的检测方法在制药工业中,溶出度(dissolution)是一种重要的参数,用来评估固体药物在溶液中的释放速度。
而对于盐酸溴己新片这种常用的药物成分,其溶出度的检测更是至关重要。
为了确保盐酸溴己新片的治疗效果,制药公司需要对其溶出度进行精确测定。
然而,由于盐酸溴己新片的特性,传统的溶出度检测方法往往存在一些局限性。
研究人员不断探索新的检测方法,以更准确、高效地评估盐酸溴己新片的溶出度。
一种最新的盐酸溴己新片溶出度检测方法基于高效液相色谱-质谱联用技术(HPLC-MS),该方法在传统的溶出度检测方法的基础上进行了革新和优化。
通过这种方法,不仅可以准确地分析盐酸溴己新片在不同时间点的溶出度曲线,还可以同时检测其代谢产物和降解物,从而更全面地了解盐酸溴己新片在溶液中的行为。
该方法利用高效液相色谱技术,可以将盐酸溴己新片及其代谢产物和降解物进行有效分离,从而确保溶出度检测的准确性。
随后,利用质谱技术对分离得到的化合物进行准确的定性和定量分析,进一步提高了检测结果的可信度。
值得一提的是,该方法还可以与自动取样系统结合,实现对多个样品的快速、连续检测,大大提高了检测效率,降低了人工操作的影响。
该方法还可以在一定程度上降低了溶出度检测的成本,适用于大规模的生产和质量控制过程。
通过对盐酸溴己新片溶出度的全面监测,制药公司可以更好地了解药物在不同条件下的释放情况,优化配方和工艺参数,从而提高产品的稳定性和疗效一致性。
这种高效的检测方法也为新药物的研发和监管提供了可靠的技术支持。
盐酸溴己新片溶出度的检测方法是制药工业中至关重要的一环。
高效液相色谱-质谱联用技术作为一种创新的检测方法,为盐酸溴己新片的溶出度检测提供了全新的思路和解决方案。
相信随着科学技术的不断进步,我们会看到更多更先进的方法应用于药物溶出度的监测,为制药行业的发展注入新的活力。
以上是个人对盐酸溴己新片溶出度检测方法的一些观点和理解,希望对你有所帮助。
高效液相色谱法测定草酸艾司西酞普兰片的含量
高效液相色谱法测定草酸艾司西酞普兰片的含量
代亚;付涛;俞丽君;陈立萍;王贤广
【期刊名称】《中国药业》
【年(卷),期】2011(20)16
【摘要】目的采用高效液相色谱法测定草酸艾司西酞普兰片的含量.方法色谱柱为C18柱(250 mm×4.6 mm,5 μm),流动相为磷酸缓冲液-甲醇(51 ∶49),检测波长为238 nm.结果艾司西酞普兰质量浓度在25 ~150 μg/mL范围内与峰面积呈良好线性关系(r=0.999 9),平均回收率为99.60%,RSD为0.44%.结论该方法简便,专属性及重现性好,可用于测定草酸艾司西酞普兰片的含量.
【总页数】2页(P32-33)
【作者】代亚;付涛;俞丽君;陈立萍;王贤广
【作者单位】浙江海森药业有限公司,浙江,杭州,322104;浙江海森药业有限公司,浙江,杭州,322104;浙江海森药业有限公司,浙江,杭州,322104;浙江海森药业有限公司,浙江,杭州,322104;浙江海森药业有限公司,浙江,杭州,322104
【正文语种】中文
【中图分类】R927.2;R971+.43
【相关文献】
1.高效液相色谱法测定米非司酮片的含量和含量均匀度 [J], 罗亚虹;陈莹;唐娟娟
2.反相高效液相色谱法测定愈创维林那敏片的含量和含量均匀度 [J], 刘慧颖;陈默;孙宽
3.高效液相色谱法测定舒必利片的含量及含量均匀度 [J], 李万平;万莉;钟潇骁
4.高效液相色谱法测定乙酰乌头碱片含量及含量均匀度 [J], 解瑞辉;郭社民;申利平
5.高效液相色谱法测定格列本脲片和格列齐特片的含量 [J], 黄艳芳;李慧敏
因版权原因,仅展示原文概要,查看原文内容请购买。
GSK1324726A_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:GSK1324726A is a novel, potent, and selective inhibitor of BET proteins with high affinity to BRD2 (IC 50=41 nM), BRD3 (IC 50=31 nM),and BRD4 (IC 50=22 nM).IC50 & Target: IC50: 22 nM (BRD4), 31 nM (BRD3), 41 nM (BRD2)[1]In Vitro: A panel of neuroblastoma cell lines are treated with GSK1324726A (I–BET726), and observed potent growth inhibition and cytotoxicity in most cell lines irrespective of MYCN copy number or expression level. All neuroblastoma cell lines tested exhibit potent growth inhibition, with a median growth IC 50 value (gIC 50; inhibitor concentration resulting in 50% growth inhibition) equal to 75 nM [1].In Vivo: GSK1324726A (I–BET726) inhibits neuroblastoma tumor growth. In the SK–N–AS model, mice in the vehicle group are euthanized on day 14 due to large tumor size. While there is no significant difference in tumor growth between the vehicle and GSK1324726A (5 mg/kg) group, 58% tumor growth inhibition (TGI) is observed in the GSK1324726A (15 mg/kg) group on day 14 of the study (n=9; p=0.006). Mice in the GSK1324726A (15 mg/kg) group are treated for an additional 7 days before tumor volume reaches a level comparable to that observed in the vehicle group, at which point the study is terminated. Tumors in the CHP–212model grow much more slowly. After 42 days, tumors in vehicle–treated mice are only half the size those in the SK–N–AS model at the end of the study (Day 14). In the CHP–212 model, treatment with 5 mg/kg GSK1324726A results in TGI equal to 50% (n=8;p=0.1816), and mice in the 15 mg/kg group exhibits a TGI of 82% at the end of the study (n=5; p=0.0488)[1].PROTOCOL (Extracted from published papers and Only for reference)Cell Assay: GSK1324726A (I–BET726) is dissolved in DMSO and stored, and then diluted with appropriate media before use [1].[1]Cell line growth–death assays are performed with a few modifications. Briefly, cells are seeded into 384–well or 96–well plates at a density optimized for 6 days of growth. The following day, T 0 measurements are taken using CellTiter–Glo, CellTiter–Fluor, or CyQuant Direct.Plates are read on an Envision, Safire 2, or SpectraMax Gemini EM plate reader. Remaining plates are treated with DMSO or a titration of GSK1324726A. Cells are incubated for 6 days and developed. Results are plotted as a percentage of the T 0 value, normalized to 100%, versus concentration of compound. A 4–parameter equation is used to generate concentration response curves. Growth IC 50(gIC 50) values are calculated at the mid–point of the growth window (between DMSO and T 0 values). Y min –T 0 values are calculated by subtracting the T 0 value (100%) from the Y min value on the curve, and are a measure of net population cell growth or death [1].Animal Administration: GSK1324726A (I–BET726) formulated as a spray dried dispersion is prepared as a suspension in 1%methylcellulose vehicle (Mice)[1].GSK1324726A (I–BET726) is formulated in DMSO and 10% (w/v) KleptoseTM in saline (2%:98%) at a concentration of 0.2mg/mL (Rat)[2].[1][2]Mice [1]CHP–212 (1×107) or SK–N–AS (5×106) cells in 100% matrigel are implanted subcutaneously into the right flank of approximately 9week old female nude (Crl:CD–1–Foxn1 nu) mice. Tumors are measured with calipers and randomized using stratified samplingProduct Name:GSK1324726A Cat. No.:HY-13960CAS No.:1300031-52-0Molecular Formula:C 25H 23ClN 2O 3Molecular Weight:434.91Target:Epigenetic Reader Domain Pathway:Epigenetics Solubility:DMSO: ≥ 46 mg/mLaccording to tumor size into treatment groups of 10 mice. GSK1324726A in vehicle or vehicle alone is administered orally by individual body weight at 10mls/kg. Mice are weighed and tumors are measured with calipers twice weekly, and mice are observed daily for any adverse treatment affects. Mice are euthanized using CO2 inhalation according to AVMA guidelines after two consecutive tumor measurements greater than 2500mm3, or if body weight loss greater than 20% is observed. For mouse pharmacodynamic studies, mice are euthanized as described above. Tumors are harvested from euthanized mice and placed in RNAlater for RNA isolation. Blood is collected after euthanasia via cardiac puncture.Rat[2]Male CD rats (253–283 g) are surgically prepared with implanted cannulae in the femoral vein (for GSK1324726A administration) and jugular vein (for blood sampling). Each rat receives Duphacillin (100 mg/kg s.c.) and Carprofen (7.5 mg/kg s.c.) as a pre–operative antibiotic and analgesic respectively. Each rat is allowed to recover for at least 2 days prior to dosing. Rats have free access to food and water throughout. Rat PK studies are conducted as a crossover design over 2 dosing occasions, with 3 days between dose administrations. Serial blood samples are taken (via indwelling jugular cannula) up to 26 h post dose administration on both dosing occasions. On study day 1, n=3 male rats each receives a 1 h intravenous infusion of GSK1324726A formulated in DMSO and 10% (w/v) KleptoseTM in saline (2%:98%) at a concentration of 0.2 mg/mL and the dose is filtered using a ca. 0.2 μm syringe filter unit. GSK1324726A is administered as a 1 h i.v. infusion at 5 mL/kg/h to achieve a target dose of 1 mg/kg. On study day 2, the same three rats each receives an oral administration of GSK1324726A suspended in 3% Pharmacoat 603/0.2% Sodium Lauryl Sulphate (w/v) aq. at a concentration of 0.6 mg/mL administered by gavage at 5 mL/kg to achieve a target dose of 3 mg/kg. At the end of the study the rats are euthanised by administration of sodium pentobarbital through the jugular vein cannula.References:[1]. Wyce A, et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS One. 2013 Aug 23; 8(8):e72967.[2]. Gosmini R, et al. The discovery of I–BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up–regulator and selective BET bromodomain inhibitor. J Med Chem. 2014 Oct 9;57(19):8111–31.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
反相高效液相色谱法测定化妆品或洗涤用品中对氯二甲苯酚、三氯卡班和三氯生
#" 结果与讨论
# ! !" 实验条件的选择 , , 资料检索[ $ ]及实验表明, 以乙腈与水或甲醇与水按不同 比例混合作 流 动 相 时, 三氯卡班和三氯生不能达到基线分 离, 即使采用梯度法, 也无济于事[ ! ]。经试验, 本方法选择四 氢呋喃 + 水 ( 体积比为 %". #" ) 作流动相可同时测定对氯二甲 苯酚、 三氯卡班和三氯生, 三组分获得很好的分离。 # ! #" 线性关系与检出限 , , 按上述色谱条件 分 别 注 入 系 列 质 量 浓 度 的 混 合 标 准 溶 测定峰面积, 以氯二 甲 苯 酚、 三氯卡班和三氯生 液各 $" ! D , 的质量浓度 ! ( %G E D ) 对相应 的 峰 面 积 " 作 图, 三 者 均 在 $" / !"" %G E D 范围内与其各 自 对 应 的 峰 面 积 呈 线 性 关 系。 其 线性回归方程分别为 " # $( !"" ! H $+ &"" ( $ I "- ’’’ ’& ) , " # +" #"" ! J # ($" ( $ I "- ’’’ #! ) 和 " I !# &"" ! H (# #"" ($ I "- ’’’ ’) ) 。经实验测定,对氯二甲苯酚、 三氯卡班和三 氯 生的最低检测量 ( % & ’ I () 分 别 为 $, "- $ 和 $ 6G , 最低检测 分别为 "- $ , "- "$ 和 "- $ %G E D 。 质量浓度 ( % & ’ I () # ! $" 精密度及回收率试验 , , 将混合标准溶液在进样量为 "- & , $- & ! G 两 个 不 同 质 量 得 到 对 氯 二 甲 苯 酚、 三氯卡班和三氯生 水平下各进样 % 次, 峰面积的 相 对 标 差 偏 差 ( KAL ) 分 别 为 "- $" , "- $& , "- $) 及
GSK1324726A_I-BET726_BET蛋白抑制剂_CAS号1300031-52-0_M9146说明书_AbMole中国
分子量434.91溶解性(25°C)DMSO ≥ 43 mg/mL分子式C25H23ClN2O3Water InsolubleCAS号1300031-52-0Ethanol储存条件3年 -20°C 粉末状生物活性GSK1324726A(I-BET726)是一种有效的选择性BET蛋白抑制剂,对BRD2,BRD3和BRD4的IC50值分别为41 nM,31 nM和22 nM。
GSK1324726A在神经母细胞瘤细胞系中,有效抑制细胞生长并诱导细胞毒性。
体内研究中,在小鼠SK-N-AS和CHP-212模型中,GSK1324726A(15 mg/kg, p.o.)抑制肿瘤生长,并下调MYCN和BCL2的表达。
在小鼠感染性休克模型中,GSK1324726A (10 mg/kg, i.v.)表现出有效的抗炎作用。
实验操作来自于公开的文献,仅供参考细胞实验细胞系方法浓度处理时间动物实验动物模型Xenograft models of non-MYCN-amplified and MYCN-amplified neuroblastoma in immunocompromised mice using the SK–N-AS and CHP-212 cell lines配制Suspended in 1% methylcellulose剂量15 mg/kg once daily给药处理p.o.不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南)小鼠大鼠兔豚鼠仓鼠狗重量 (kg)0.020.15 1.80.40.0810体表面积 (m)0.0070.0250.150.050.020.5K系数36128520动物 A (mg/kg) = 动物 B (mg/kg) ×动物 B的K系数动物 A的K系数例如,依据体表面积折算法,将白藜芦醇用于小鼠的剂量22.4 mg/kg 换算成大鼠的剂量,需要将22.4 mg/kg 乘以小鼠的K系数(3),再除以大鼠的K系数(6),得到白藜芦醇用于大鼠的等效剂量为11.2 mg/kg。
药物GLP认证目录(2022版)
中国药科大学
(新药安全评价
研究中心)
单次和多次给药毒性试验(非啮齿类,灵长类)
GLP21007126
广州医药研究总院有限公司(药物非临床评价研究中心)
1.生殖毒性试验(Ш段)
2.致癌试验
GLP21008127
西咸新区国睿一诺药物安全评价研究有限公司
1.遗传毒性试验(Ames、微核、染色体畸变)
药物GLP认证目录
机 构 名 称
试 验 项 目
认证批件编号
湖南普瑞玛药物研究中心有限公司
1.单次和多次给药毒性试验(啮齿类)
2.单次和多次给药毒性试验(非啮齿类)
3.生殖毒性试验(I段、II段、Ш段)
4.遗传毒性试验(Ames、微核、染色体畸变)
5.局部毒性试验
6.免疫原性试验
安全性药理试验
8.毒代动力学试验
生殖毒性试验(Ш段)
GLP21017136
益诺思生物技术南通有限公司
1.致癌试验
2.免疫原性试验
GLP21020139
上海益诺思生物技术股份有限公司
依赖性试验
GLP22001140
江苏鼎泰药物研究股份有限公司
生殖毒性试验(Ш段)
GLP22002141
1.单次和多次给药毒性试验(非啮齿类)
2.免疫原性试验
3.安全性药理试验
4.依赖性试验
GLP21015134
广州博济医药生物技术股份有限公司
(药物评价中心)
1.单次和多次给药毒性试验(非啮齿类,灵长类)
2.生殖毒性试验(I段、II段)
3.免疫原性试验
GLP21016135
山东省医学科学院药物研究所
(山东省医学科学院药物安全评价中心)
高效液相色谱法测定艾司唑仑的物质
高效液相色谱法(HPLC)是一种常用的分析方法,可以用于测定艾司唑仑的物质。
以下是测定步骤:
1. 准备试剂:流动相(乙腈:水,50:50),艾司唑仑标准品,色谱纯有机溶剂(如甲醇或乙腈),去离子水,色谱柱(C18柱)。
2. 配置标准溶液:将艾司唑仑标准品用流动相溶解,制备成一定浓度的标准溶液。
3. 进行色谱分析:将标准溶液注入液相色谱仪,以一定流速通过色谱柱,分离出艾司唑仑。
4. 检测:使用紫外检测器(UV detector)对艾司唑仑进行检测。
检测波长通常为229nm。
5. 记录色谱图:记录艾司唑仑的色谱峰及峰面积。
6. 进行定量分析:将标准溶液的浓度与对应的峰面积绘制成标准曲线。
通过待测样品中艾司唑仑的峰面积,根据标准曲线计算其浓度。
7. 进行定性分析:根据艾司唑仑的保留时间进行定性分析。
在相同条件下,待测样品中艾司唑仑的保留时间应与标准品的保留时间一致。
需要注意的是,在实验过程中要注意实验室环境的控制,避免交叉污染。
此外,实验过程中应严格遵守实验室安全规范,确保人员和设备的安全。
高效液相色谱法测定复方苯硝那敏片中维生素B6、苯巴比妥、马来酸氯苯那敏和硝西泮含量
高效液相色谱法测定复方苯硝那敏片中维生素B6、苯巴比妥、马来酸氯苯那敏和硝西泮含量谭生建;刘刚;王海涛;赵森;姜韧;张华【期刊名称】《药学实践杂志》【年(卷),期】2008(26)4【摘要】目的:建立HPLC同时测定复方苯硝那敏片中维生素B6、苯巴比妥、马来酸氯苯那敏和硝西泮含量的方法.方法:色谱柱用十八烷基硅烷键合硅胶为固定相(150 mm ×4.6 mm,4.6μm).流动相A:乙腈-水-三乙胺(100∶900∶1,含0.01mol/L庚烷磺酸钠,用冰醋酸调pH值3.5),流动相B:乙腈.洗脱程序:0~12min,A100%~70%;12~200 min,A 70%;流速:1 mL/min,检测波长260 nm.结果:维生素B6、苯巴比妥、马来酸氯苯那敏和硝西泮的保留时间分别约为4.6、10.2、12.3和14.3 min,与各自相邻峰的分离度均大于1.5.以峰面积对进样量(μg)线性回归,维生素B6回归方程:y=251.4x+2.403,线性范围:0.168 4~2.021 μg,r=0.999 8;苯巴比妥回归方程:y=145.8x+1.612,线性范围:0.510 8~6.130 μg,r=0.999 9;马来酸氯苯那敏回归方程:y=697.3x-7.252,线性范围:0.122 8~1.474 μg,r=0.999 9;硝西泮回归方程:y=2 767x+17.75,线性范围:0.049 60~0.595 2 μg,r=0.999 8.维生素B6苯巴比妥、马来酸氯苯那敏和硝西泮回收率分别为100.1%、99.4%、99.3%和100.7%,RSD分别为0.18%、0.13%、0.47%和0.16%.结论:本方法精密度、准确度好,操作简便,可用于复方苯硝那敏片中维生素B6、苯巴比妥、马来酸氯苯那敏和硝西泮含量测定.【总页数】4页(P286-289)【作者】谭生建;刘刚;王海涛;赵森;姜韧;张华【作者单位】中国人民解放军第306医院药学部,北京,100101;中国人民解放军第306医院药学部,北京,100101;中国人民解放军第306医院药学部,北京,100101;中国人民解放军第306医院药学部,北京,100101;中国人民解放军第306医院药学部,北京,100101;中国人民解放军第306医院药学部,北京,100101【正文语种】中文【中图分类】R927.2【相关文献】1.HPLC法测定复方苯硝那敏片中苯巴比妥马来酸氯苯那敏和硝西泮含量 [J], 谭生建;刘刚;张捷;刘昌叶;潘敏翔2.高效液相色谱法测定复方双嗪利血平片中硫酸双肼屈嗪维生素B1维生素B6的含量 [J], 李海妮3.高效液相色谱法测定复方茶新那敏片中马来酸氯苯那敏含量 [J], 刘杨;赖庆宽4.离子对高效液相色谱法测定复方甲硝唑片中甲硝唑和维生素B6含量 [J], 王自然;伏光华5.高效液相色谱法测定复方银翘氨敏胶囊中马来酸氯苯那敏含量及含量均匀度 [J], 吴晓燕;唐琨;尚春燕因版权原因,仅展示原文概要,查看原文内容请购买。
高效液相色谱法测定拜阿司匹灵泡腾片中维生素C的含量
高效液相色谱法测定拜阿司匹灵泡腾片中维生素C的含量
杨颖
【期刊名称】《药物分析杂志》
【年(卷),期】1998(18)4
【摘要】高效液相色谱法测定拜阿司匹灵泡腾片中维生素C的含量广州市药品检
验所510160杨颖拜阿司匹灵泡腾片是德国拜耳公司生产的解热镇痛复方制剂,每片含乙酰水杨酸400mg,维生素C240mg。
厂附资料中维生素C含量测定采用碘量法,本文采用极性的氨基柱[1],...
【总页数】2页(P274-275)
【关键词】阿司匹林;泡腾片;维生素C
【作者】杨颖
【作者单位】广州市药品检验所
【正文语种】中文
【中图分类】R977.23;R927.2
【相关文献】
1.反相高效液相色谱法测定复方维生素泡腾片中维生素C的含量 [J], 薛继雄;刘金来
2.高效液相色谱法测定维生素C咀嚼片和泡腾片中木糖醇、山梨醇和蔗糖的含量[J], 刁飞燕;刘春霖;吴晓云;李启艳
3.高效液相色谱法测定维生素C泡腾片有关物质含量 [J], 宁丽;孙华伟;于红霞
4.高效液相色谱法测定维生素C泡腾片有关物质含量 [J], 林倩;刘桢;翟翠云
因版权原因,仅展示原文概要,查看原文内容请购买。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Oct.-09-2018Print Date:Oct.-09-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :GSK1324726ACatalog No. :HY-13960CAS No. :1300031-52-01.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 4),H302Acute aquatic toxicity (Category 1),H400Chronic aquatic toxicity (Category 1),H4102.2 GHS Label elements, including precautionary statementsPictogramSignal word WarningHazard statement(s)H302 Harmful if swallowed.H410 Very toxic to aquatic life with long lasting effects.Precautionary statement(s)P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.P273 Avoid release to the environment.P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor ⁄ physician if you feel unwell.P330 Rinse mouth.P391 Collect spillage.P501 Dispose of contents ⁄ container to an approved waste disposal plant.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:I-BET726;GSK 1324726A;GSK-1324726A;I-BET 726Formula:C25H23ClN2O3Molecular Weight:434.91CAS No. :1300031-52-04. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGUN number: 3077Class: 9Packing group: IIIEMS-No: F-A, S-FProper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.Marine pollutant: Marine pollutant.IATAUN number: 3077Class: 9Packing group: IIIProper shipping name: Environmentally hazardous substance, solid, n.o.s.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。